Click Therapeutics laid off 25 employees, representing over 25% of its staff, to restructure for commercialization of CT-155.1
The layoffs follow a restructured partnership with Boehringer Ingelheim, where Boehringer transferred full commercial and marketing authorization rights for CT-155 to Click and provided a $50 million Series D investment plus dedicated commercial funding.127
CT-155 is a prescription digital therapeutic for negative symptoms of schizophrenia, which met its primary endpoint in phase 3 trials in October and received FDA breakthrough device designation in 2024.27
The original 2020 deal valued over $500 million had Click handling R&D while Boehringer managed commercialization; the new strategic agreement shifts that responsibility to Click.2
Sources:
1. https://insights.citeline.com/medtech-insight/business/strategy/click-therapeutics-cuts-over-25-of-staff-after-50m-raise-ct-155-commercial-shift-LZH63JQ3UREU3FX74V32GUE3XE/
2. https://www.fiercebiotech.com/medtech/boehringer-hands-over-funding-commercialisation-rights-clicks-digital-therapeutic
7. https://insights.citeline.com/medtech-insight/business/deals/boehringer-hands-ct-155-commercial-rights-to-click-therapeutics-in-50m-deal-restructure-GVU4Q75IX5FNFJ7K6MWQQDB6EY/